Syngene International Share News - Latest Updates, Live News & More

Latest news about Syngene International

Syngene International Receives Positive USFDA Updates for Bengaluru Facilities 3 days ago

Syngene International announced positive outcomes from USFDA inspections of two Bengaluru facilities. The Semicon Park facility passed a Good Clinical Practice inspection with zero observations, classified as 'No Action Indicated'. The Biocon Park SEZ facility received an Establishment Inspection Report, classified as 'Voluntary Action Indicated', with USFDA accepting the company's Corrective and Preventive Action plans. These results validate Syngene's regulatory compliance and quality assurance measures, potentially boosting client confidence without impacting financials or operations.

Syngene International's Bengaluru Unit Passes FDA Inspection with VAI Classification 5 days ago

Syngene International Sees Significant Block Trade on NSE 7 days ago

Syngene International Sees Block Trade of 284,191 Shares Worth ₹18.90 Crore 7 days ago

Syngene International Shares See Significant Block Trade on NSE May 27, 2025

More news about Syngene International

12May 25

Syngene International Witnesses Significant Block Trade Worth ₹25.02 Crore

A block trade of 403,379 shares of Syngene International Ltd. was executed on the National Stock Exchange at ₹620.20 per share, totaling ₹25.02 crore. This significant transaction has drawn attention from market observers due to its size and potential impact on the stock. Syngene, a leading contract research and manufacturing organization in the pharmaceutical and biotechnology sector, continues to attract interest from institutional investors.

24Apr 25

Syngene International Reports Strong Q4 Growth, Full-Year Revenue Up 4%

Syngene International Limited reported robust Q4 FY25 results with revenue crossing Rs. 1,000 crore for the first time, up 11% year-on-year. Full-year FY25 revenue grew 4% to Rs. 3,642.00 crore. The company acquired a biologics manufacturing facility in the US, expanding its capacity to 50,000L. For FY26, Syngene expects early teens revenue growth on an underlying basis, with EBITDA margin moderating to mid-twenties. A final dividend of Rs. 1.25 per share was recommended for FY25.

24Apr 25

Syngene International: Shares Plummet 10% on Revenue Miss and Weak FY26 Outlook

Syngene International reported mixed Q4 FY25 results with revenue growth of 11% to Rs. 1,018.00 crore, missing analyst expectations. The company's shares fell 10% following the announcement due to disappointing Q4 performance and weak FY26 guidance. For FY26, Syngene projects single-digit growth, lower than the expected 15%. EBITDA margins declined to 33.70% in Q4 FY25. Despite Q4 setbacks, full-year FY25 revenue grew 4% to Rs. 3,642.00 crore. The company acquired a biologics manufacturing facility in the US, expanding its capacity to 50,000L for large molecule services.

23Apr 25

Syngene International Reports Strong Q4 Growth, Expands US Presence with Strategic Acquisition

Syngene International's Q4 FY25 revenue crossed Rs. 1,018 crore, up 11% YoY. Full-year revenue reached Rs. 3,642 crore, a 4% increase. The company acquired a biologics manufacturing facility in Baltimore, USA, expanding its capacity to 50,000L. Despite global uncertainties, Syngene expects early teens revenue growth in FY26, with EBITDA margin moderating to mid-twenties due to new facility costs.

23Apr 25

Syngene International: Q4 Profit Dips 3%, FY25 Revenue Grows 4%

Syngene International's Q4 FY25 results show a 11% YoY revenue increase to Rs 1,018.00 crore, but a 3% YoY profit decline to Rs 183.00 crore. Full-year FY25 revenue grew 4% to Rs 3,714.00 crore, while profit after tax fell 8% to Rs 475.00 crore. The company announced a final dividend of Rs 1.25 per share. For FY26, Syngene expects early teens revenue growth on an underlying basis, but anticipates EBITDA margin moderation and a decline in profit after tax.

03Apr 25

Syngene International Shares See Massive Block Trade on NSE

A significant block trade of 1,014,870 shares of Syngene International Ltd. occurred on the NSE at Rs. 748.40 per share, totaling Rs. 75.95 crores. This large transaction has drawn market attention, potentially signaling shifts in institutional holdings or strategic moves by major investors. While the identities of the traders remain undisclosed, such trades can influence short-term market sentiment and trading patterns.

01Apr 25

Syngene International Appoints Peter Bains as New MD and CEO, Marking a Strategic Leadership Transition

Syngene International has appointed Peter Bains as its new Managing Director and CEO, effective April 1, 2025. Bains, 67, brings over 30 years of experience in the global biopharmaceutical industry. He previously served as Syngene's CEO from 2010 to 2015, leading the company to its public listing. Bains has held leadership roles at Biocon Group, Sosei Group, and spent 23 years at GlaxoSmithKline. His appointment is for a two-year term, subject to shareholder approval.

11Mar 25

Syngene International Expands Global Footprint with First US Biologics Facility Acquisition

Syngene International has acquired a biologics manufacturing facility in Baltimore, USA, for $36.5 million, with a total investment of $50 million including upgrades. This acquisition will increase Syngene's single-use bioreactor capacity to 50,000L and is expected to be operational by the second half of 2025. The company also plans to invest up to $56 million in its US subsidiary, Syngene USA Inc. The move strengthens Syngene's global presence, particularly in the US market, and expands its biologics capabilities.

10Mar 25

Syngene International Expands Global Footprint with $50 Million US Biologics Facility Acquisition and $56 Million Investment in US Subsidiary

Syngene International Limited is acquiring its first biologics manufacturing site in the US for $36.5 million, with plans to invest an additional $13.5 million to make it operational. The company will also invest up to $56 million in its US subsidiary. Located in Baltimore, the facility will increase Syngene's total single-use bioreactor capacity to 50,000L and is expected to be operational by the second half of 2025. This strategic move enhances Syngene's global presence, addresses growing US demand, and expands its service offerings in monoclonal antibody manufacturing.

24Feb 25

Syngene International Faces FDA Scrutiny: Form 483 Issued for Bengaluru Facilities

The U.S. FDA has issued a Form 483 with five observations for Syngene International's Bengaluru facilities, indicating potential violations of good manufacturing practices. This regulatory action may impact Syngene's compliance status, quality control processes, and U.S. market operations. The company is expected to review the observations, develop a corrective action plan, and respond to the FDA.

21Feb 25

Syngene International Faces USFDA Scrutiny: 5 Observations Issued for Bengaluru Facilities

Syngene International's Bengaluru facilities underwent a USFDA inspection from February 10-20, 2025, resulting in a Form 483 with five observations. The inspection focused on commercial manufacturing for the US market. Syngene has committed to addressing these observations comprehensively within the stipulated time. The impact on operations and the company's ability to resolve these issues promptly will be crucial for maintaining its market position and regulatory compliance.